Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
7.28% $3.24
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2.44 mill |
EPS: | -33.63 |
P/E: | -0.100 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 0.754 mill |
Avg Daily Volume: | 0.0280 mill |
RATING 2024-04-17 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.100 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -0.100 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.964 (-39.37%) $-1.276 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 2.40 - 4.08 ( +/- 26.02%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-02 | Cleaver Heath | Buy | 10 000 | Common Stock Option (right to buy) |
2023-05-02 | Aubert Paul | Buy | 10 000 | Common Stock Option (right to buy) |
2023-05-02 | Sherwood Aline | Buy | 10 000 | Common Stock Option (right to buy) |
2023-05-02 | Morris Douglas P | Buy | 13 000 | Common Stock Option (right to buy) |
2023-05-02 | Nielsen Peter Henry | Buy | 105 000 | Common Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 88 transactions |
Buy: 10 429 808 | Sell: 661 335 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.24 (7.28% ) |
Volume | 0.702 mill |
Avg. Vol. | 0.0280 mill |
% of Avg. Vol | 2 504.92 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.